LIVN LivaNova (LIVN) Q1 FY26 earnings call
LivaNova delivered a strong first quarter, exceeding expectations with double-digit revenue growth across its core cardiopulmonary and epilepsy businesses. The company raised its full-year revenue guidance, reflecting robust performance driven by the Essenz upgrade cycle, market share gains in consumables, and improved U.S. reimbursement for VNS therapy. Strategic investments in innovation, particularly for the obstructive sleep apnea (OSA) program, are progressing with key regulatory and clinical milestones achieved, positioning the company for future high-growth market entry.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.